Cargando…

A Network Pharmacology Approach to Explore the Mechanism of HuangZhi YiShen Capsule for Treatment of Diabetic Kidney Disease

BACKGROUND AND OBJECTIVE: HuangZhi YiShen Capsule (HZYS) is a Chinese patent herbal drug that protects kidney function in diabetic kidney disease (DKD) patients. However, the pharmacologic mechanisms of HZYS remain unclear. This study would use network pharmacology to explore the pharmacologic mecha...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xue-Feng, Zhou, Wei-E, Liu, Wen-Jing, Luo, Min-Jing, Wu, Xia-Qing, Wang, Ying, Liu, Peng, Wen, Yu-Min, Li, Jia-Lin, Zhao, Ting-Ting, Zhang, Hao-Jun, Zhao, Hai-Ling, Li, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386324/
https://www.ncbi.nlm.nih.gov/pubmed/34497749
http://dx.doi.org/10.2478/jtim-2021-0020
_version_ 1783742237903945728
author Zhou, Xue-Feng
Zhou, Wei-E
Liu, Wen-Jing
Luo, Min-Jing
Wu, Xia-Qing
Wang, Ying
Liu, Peng
Wen, Yu-Min
Li, Jia-Lin
Zhao, Ting-Ting
Zhang, Hao-Jun
Zhao, Hai-Ling
Li, Ping
author_facet Zhou, Xue-Feng
Zhou, Wei-E
Liu, Wen-Jing
Luo, Min-Jing
Wu, Xia-Qing
Wang, Ying
Liu, Peng
Wen, Yu-Min
Li, Jia-Lin
Zhao, Ting-Ting
Zhang, Hao-Jun
Zhao, Hai-Ling
Li, Ping
author_sort Zhou, Xue-Feng
collection PubMed
description BACKGROUND AND OBJECTIVE: HuangZhi YiShen Capsule (HZYS) is a Chinese patent herbal drug that protects kidney function in diabetic kidney disease (DKD) patients. However, the pharmacologic mechanisms of HZYS remain unclear. This study would use network pharmacology to explore the pharmacologic mechanisms of HZYS. METHODS: Chemical constituents of HZYS were obtained through the Traditional Chinese Medicine Systems Pharmacology Database (TCMSP) and literature search. Potential targets of HZYS were identified by using the TCMSP and the SwissTarget Prediction databases. DKD-related target genes were collected by using the Online Mendelian Inheritance in Man, Therapeutic Target Database, GeneCards, DisGeNET, and Drugbank databases. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were carried out to further explore the mechanisms of HZYS in treating DKD. Molecular docking was conducted to verify the potential interactions between the prime compounds and the hub genes. RESULTS: 179 active compounds and 620 target genes were obtained, and 571 common targets were considered potential therapeutic targets. The top 10 main active compounds of HZYS were heparin, quercetin, kaempferol, luteolin, methyl14-methylpentadecanoate, methyl (Z)-11-hexadecenoate, 17-hydroxycorticosterone, 4-pregnene-17α, 20β, 21-triol-3, 11-dione, wogonin, and hydroxyecdysone. Hub signaling pathways by which HZYS treating DKD were PI3K-Akt, MAPK, AGE-RAGE in diabetic complications, TNF, and apoptosis. The top 10 target genes associated with these pathways were IL6, MAPK1, AKT1, RELA, BCL2, JUN, MAPK3, MAP2K1, CASP3, and TNF. Quercetin and Luteolin were verified to have good binding capability with the hub potential targets IL6, MAPK1, AKT1 through molecular docking. CONCLUSION: HZYS appeared to treat DKD by regulating the inflammatory, oxidative stress, apoptotic, and fibrosis signaling pathways. This study provided a novel perspective for further research of HZYS.
format Online
Article
Text
id pubmed-8386324
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Sciendo
record_format MEDLINE/PubMed
spelling pubmed-83863242021-09-07 A Network Pharmacology Approach to Explore the Mechanism of HuangZhi YiShen Capsule for Treatment of Diabetic Kidney Disease Zhou, Xue-Feng Zhou, Wei-E Liu, Wen-Jing Luo, Min-Jing Wu, Xia-Qing Wang, Ying Liu, Peng Wen, Yu-Min Li, Jia-Lin Zhao, Ting-Ting Zhang, Hao-Jun Zhao, Hai-Ling Li, Ping J Transl Int Med Original Article BACKGROUND AND OBJECTIVE: HuangZhi YiShen Capsule (HZYS) is a Chinese patent herbal drug that protects kidney function in diabetic kidney disease (DKD) patients. However, the pharmacologic mechanisms of HZYS remain unclear. This study would use network pharmacology to explore the pharmacologic mechanisms of HZYS. METHODS: Chemical constituents of HZYS were obtained through the Traditional Chinese Medicine Systems Pharmacology Database (TCMSP) and literature search. Potential targets of HZYS were identified by using the TCMSP and the SwissTarget Prediction databases. DKD-related target genes were collected by using the Online Mendelian Inheritance in Man, Therapeutic Target Database, GeneCards, DisGeNET, and Drugbank databases. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were carried out to further explore the mechanisms of HZYS in treating DKD. Molecular docking was conducted to verify the potential interactions between the prime compounds and the hub genes. RESULTS: 179 active compounds and 620 target genes were obtained, and 571 common targets were considered potential therapeutic targets. The top 10 main active compounds of HZYS were heparin, quercetin, kaempferol, luteolin, methyl14-methylpentadecanoate, methyl (Z)-11-hexadecenoate, 17-hydroxycorticosterone, 4-pregnene-17α, 20β, 21-triol-3, 11-dione, wogonin, and hydroxyecdysone. Hub signaling pathways by which HZYS treating DKD were PI3K-Akt, MAPK, AGE-RAGE in diabetic complications, TNF, and apoptosis. The top 10 target genes associated with these pathways were IL6, MAPK1, AKT1, RELA, BCL2, JUN, MAPK3, MAP2K1, CASP3, and TNF. Quercetin and Luteolin were verified to have good binding capability with the hub potential targets IL6, MAPK1, AKT1 through molecular docking. CONCLUSION: HZYS appeared to treat DKD by regulating the inflammatory, oxidative stress, apoptotic, and fibrosis signaling pathways. This study provided a novel perspective for further research of HZYS. Sciendo 2021-06-18 /pmc/articles/PMC8386324/ /pubmed/34497749 http://dx.doi.org/10.2478/jtim-2021-0020 Text en © 2021 Xue-Feng Zhou et al., published by Sciendo https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
spellingShingle Original Article
Zhou, Xue-Feng
Zhou, Wei-E
Liu, Wen-Jing
Luo, Min-Jing
Wu, Xia-Qing
Wang, Ying
Liu, Peng
Wen, Yu-Min
Li, Jia-Lin
Zhao, Ting-Ting
Zhang, Hao-Jun
Zhao, Hai-Ling
Li, Ping
A Network Pharmacology Approach to Explore the Mechanism of HuangZhi YiShen Capsule for Treatment of Diabetic Kidney Disease
title A Network Pharmacology Approach to Explore the Mechanism of HuangZhi YiShen Capsule for Treatment of Diabetic Kidney Disease
title_full A Network Pharmacology Approach to Explore the Mechanism of HuangZhi YiShen Capsule for Treatment of Diabetic Kidney Disease
title_fullStr A Network Pharmacology Approach to Explore the Mechanism of HuangZhi YiShen Capsule for Treatment of Diabetic Kidney Disease
title_full_unstemmed A Network Pharmacology Approach to Explore the Mechanism of HuangZhi YiShen Capsule for Treatment of Diabetic Kidney Disease
title_short A Network Pharmacology Approach to Explore the Mechanism of HuangZhi YiShen Capsule for Treatment of Diabetic Kidney Disease
title_sort network pharmacology approach to explore the mechanism of huangzhi yishen capsule for treatment of diabetic kidney disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386324/
https://www.ncbi.nlm.nih.gov/pubmed/34497749
http://dx.doi.org/10.2478/jtim-2021-0020
work_keys_str_mv AT zhouxuefeng anetworkpharmacologyapproachtoexplorethemechanismofhuangzhiyishencapsulefortreatmentofdiabetickidneydisease
AT zhouweie anetworkpharmacologyapproachtoexplorethemechanismofhuangzhiyishencapsulefortreatmentofdiabetickidneydisease
AT liuwenjing anetworkpharmacologyapproachtoexplorethemechanismofhuangzhiyishencapsulefortreatmentofdiabetickidneydisease
AT luominjing anetworkpharmacologyapproachtoexplorethemechanismofhuangzhiyishencapsulefortreatmentofdiabetickidneydisease
AT wuxiaqing anetworkpharmacologyapproachtoexplorethemechanismofhuangzhiyishencapsulefortreatmentofdiabetickidneydisease
AT wangying anetworkpharmacologyapproachtoexplorethemechanismofhuangzhiyishencapsulefortreatmentofdiabetickidneydisease
AT liupeng anetworkpharmacologyapproachtoexplorethemechanismofhuangzhiyishencapsulefortreatmentofdiabetickidneydisease
AT wenyumin anetworkpharmacologyapproachtoexplorethemechanismofhuangzhiyishencapsulefortreatmentofdiabetickidneydisease
AT lijialin anetworkpharmacologyapproachtoexplorethemechanismofhuangzhiyishencapsulefortreatmentofdiabetickidneydisease
AT zhaotingting anetworkpharmacologyapproachtoexplorethemechanismofhuangzhiyishencapsulefortreatmentofdiabetickidneydisease
AT zhanghaojun anetworkpharmacologyapproachtoexplorethemechanismofhuangzhiyishencapsulefortreatmentofdiabetickidneydisease
AT zhaohailing anetworkpharmacologyapproachtoexplorethemechanismofhuangzhiyishencapsulefortreatmentofdiabetickidneydisease
AT liping anetworkpharmacologyapproachtoexplorethemechanismofhuangzhiyishencapsulefortreatmentofdiabetickidneydisease
AT zhouxuefeng networkpharmacologyapproachtoexplorethemechanismofhuangzhiyishencapsulefortreatmentofdiabetickidneydisease
AT zhouweie networkpharmacologyapproachtoexplorethemechanismofhuangzhiyishencapsulefortreatmentofdiabetickidneydisease
AT liuwenjing networkpharmacologyapproachtoexplorethemechanismofhuangzhiyishencapsulefortreatmentofdiabetickidneydisease
AT luominjing networkpharmacologyapproachtoexplorethemechanismofhuangzhiyishencapsulefortreatmentofdiabetickidneydisease
AT wuxiaqing networkpharmacologyapproachtoexplorethemechanismofhuangzhiyishencapsulefortreatmentofdiabetickidneydisease
AT wangying networkpharmacologyapproachtoexplorethemechanismofhuangzhiyishencapsulefortreatmentofdiabetickidneydisease
AT liupeng networkpharmacologyapproachtoexplorethemechanismofhuangzhiyishencapsulefortreatmentofdiabetickidneydisease
AT wenyumin networkpharmacologyapproachtoexplorethemechanismofhuangzhiyishencapsulefortreatmentofdiabetickidneydisease
AT lijialin networkpharmacologyapproachtoexplorethemechanismofhuangzhiyishencapsulefortreatmentofdiabetickidneydisease
AT zhaotingting networkpharmacologyapproachtoexplorethemechanismofhuangzhiyishencapsulefortreatmentofdiabetickidneydisease
AT zhanghaojun networkpharmacologyapproachtoexplorethemechanismofhuangzhiyishencapsulefortreatmentofdiabetickidneydisease
AT zhaohailing networkpharmacologyapproachtoexplorethemechanismofhuangzhiyishencapsulefortreatmentofdiabetickidneydisease
AT liping networkpharmacologyapproachtoexplorethemechanismofhuangzhiyishencapsulefortreatmentofdiabetickidneydisease